Longevity network
Longevity Centers of America (Netzwerk)
- Hormone therapy (HRT / BHRT)
- Peptide therapy
ListedView profile →
§ — Substance profile
A
Tirzepatide
Mounjaro · Zepbound · Dual GIP/GLP-1 receptor agonist
01 — Regulatory status
Regulatory status · United States · as of September 2026
FDA-approved for type 2 diabetes (Mounjaro), chronic weight management and obstructive sleep apnea in obesity (Zepbound). Compounding permitted only during declared shortages; shortage status must be verified.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
- Approved drug with randomized controlled trials for the approved indication
- Human clinical data exists, but no approval for the researched use
- Animal or in-vitro data only, no controlled human trials
- No published clinical data; use rests on anecdote
A
B
C
D
Reviewed September 2026 · Sources: FDA, EMA
02 — Researched for
What is being studied.
Obesity, type 2 diabetes, sleep apnea, heart failure with preserved ejection fraction, cardiovascular outcomes.
03 — What the evidence shows
The published record.
Randomized trials show roughly 20% mean weight loss at 72 weeks at the highest dose, the largest effect of any approved anti-obesity drug to date.
04 — What is claimed but not shown
Claimed, not demonstrated.
Superior long-term cardiovascular benefit over semaglutide; benefit in normal-weight adults.
05 — Known risks
Documented risks.
As for GLP-1 agonists; higher rates of gastrointestinal adverse events at top doses; weight regain after discontinuation.
06 — Researched for these goals
Where Tirzepatide appears.
Related substances
07 — Questions for your physician
Six questions worth printing.
- 01What is your primary board certification, and in what year did you obtain it?
- 02Is this peptide approved for what you are prescribing it for — and if not, what is the legal basis on which you are supplying it?
- 03Which human trials support this use, and what were their size and duration?
- 04Where does the product come from, and can you show me a certificate of analysis for this batch?
- 05What outcome will we measure, when, and what happens if it does not improve?
- 06What is the total cost for the first three months, in writing?
Providers offering peptide therapy
Listing in the registry is not an endorsement of any substance or protocol, and it is not a statement that a treatment is approved.
Reviewed September 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.